Language of Resource
Full Text Available
Open Access / OK to Reproduce
The aim of this presentation is to examine the safety profile of injectable
hydromorphone and diacetylmorphine by analyzing rates of adverse
events (AEs) in the SALOME study and exploring if they were
associated with dose and patterns of treatment attendance.
When injectable hydromorphone and diacetylmorphine are individually dosed and monitored, their opioid-related side effects, including potential fatal overdoses, are safely mitigated and treated by health care providers. Related adverse events did not lead to more missed treatment days and the dose prescribed does not seem to play a direct or sole role.